Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C.
Phase of Trial: Phase I/II
Latest Information Update: 04 Feb 2013
At a glance
- Drugs Interferon alpha 5 (Primary) ; Peginterferon alfa-2b
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 New trial record